Editorial on First-Time Disclosures of Clinical ... - ACS Publications


Editorial on First-Time Disclosures of Clinical...

2 downloads 47 Views 211KB Size

Editorial pubs.acs.org/jmc

Cite This: J. Med. Chem. XXXX, XXX, XXX−XXX

Editorial on First-Time Disclosures of Clinical Candidates

O

ver several years, the Division of Medicinal Chemistry (MEDI) has been sponsoring symposia at ACS National Meetings on “First Time Disclosure of Clinical Candidates”. The sessions have garnered major interest from meeting attendees, as these excellent presentations have been very informative about the newest drug candidates of potential clinical significance. At the 254th ACS National Meeting in Washington, DC, and the 255th ACS National Meeting in New Orleans, LA, there were day-long sessions, organized by Jacob Schwarz on the Wednesdays of each meeting, in which 10 different lectures were delivered on diverse drug candidates and leading drug targets. Because these popular lectures have only been available to the meeting attendees and via the short ACS abstracts, the broader scientific community has largely missed out on the details of these hot, new advances. Given limited travel budgets and/or limited travel opportunities, many medicinal chemists and chemical biologists will likely continue to be unable to attend the national meetings and will thereby not benefit from this valuable wellspring of information. The Editors of ACS Medicinal Chemistry Letters (ACSMCL) and Journal of Medicinal Chemistry (JMC) have decided to join forces to bring the content of these symposia to the scientific community through the agency of their respective forums. This publication initiative will be conveyed in two different forms: short articles in ACSMCL or long articles in JMC. Authors of the meeting presentations will be invited to submit manuscripts that cover their lecture content and be given the choice of a short or long version. Given that the materials presented in these symposia would have necessarily been approved by their organizations prior to the public disclosures, we envision that manuscripts describing the content of the presentations could be rapidly prepared and submitted for publication in one of our journals. The choice of which forum will ultimately depend on how much SAR detail and pharmacological results can be disclosed to our readership in print form. These feature articles will appear in regular issues of the journals, and a collection of them will be assembled into Virtual Issues of the journal from time to time, entitled “First-Time Disclosures of Clinical Candidates”. The article category in ACSMCL will be a “Note” and in JMC will be a “Drug Annotation”.

Bruce E. Maryanoff



Department of Chemistry, The Scripps Research Institute

AUTHOR INFORMATION

ORCID

Bruce E. Maryanoff: 0000-0003-3590-2357 Notes

Views expressed in this editorial are those of the author and not necessarily the views of the ACS.

© XXXX American Chemical Society

A

DOI: 10.1021/acs.jmedchem.8b00739 J. Med. Chem. XXXX, XXX, XXX−XXX